1389326-22-0

Upstream product

• 1389323-98-1 methyl (4-chlorophenyl)(4-nitro-1H-indol-1-yl)acetate 
• 1389326-20-8 methyl (4-amino-1H-indol-1-yl)(4-chlorophenyl)acetate 
• 52449-43-1 (4-chloro-phenyl)-acetic acid methyl ester 
• 4769-97-5 4-nitro-1H-indoIe 
• 1389326-21-9 methyl {4-[(tert-butoxycarbonyl)amino]-1H-indol-1-yl}(4-chlorophenyl)acetate 
• 75-03-6 ethyl iodide 
• 24091-92-7 methyl 2-bromo-2-(4-chlorophenyl)acetate 

Downstream Products

• 1389324-89-3 (R)-N-{1-[(2R)-2-(4-chlorophenyl)-1-hydroxybutan-2-yl]-1H-indol-4-yl}methanesulfonamide 
• 1389326-42-4 methyl 2-(4-chlorophenyl)-2-(4-(2,5-dimethyl-1H-pyrrol-1-yl)-1H-indol-1-yl)butanoate 
• 1389326-43-5 2-(4-chlorophenyl)-2-(4-(2,5-dimethyl-1H-pyrrol-1-yl)-1H-indol-1-yl)butan-1-ol 
• 1389326-44-6 1-(2-(4-chlorophenyl)-1-methoxybutan-2-yl)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1H-indole 
• 1389326-45-7 1-(2-(4-chlorophenyl)-1-methoxybutan-2-yl)-1H-indol-4-amine 
• 1389325-05-6 N-(1-(2-(4-chlorophenyl)-1-methoxybutan-2-yl)-1H-indol-4-yl)methanesulfonamide 
• 1389325-08-9 N-(1-(3-(4-chlorophenyl)-2-oxopentan-3-yl)-1H-indol-4-yl)methanesulfonamide 
• 1389326-57-1 tert-butyl 1-(2-(4-chlorophenyl)-1-hydroxybutan-2-yl)-1H-indol-4-ylcarbamate 
• 1389326-59-3 tert-butyl 1-(2-(4-chlorophenyl)-1-cyanobutan-2-yl)-1H-indol-4-ylcarbamate 
• 1389326-60-6 3-(4-amino-1H-indol-1-yl)-3-(4-chlorophenyl)pentanenitrile 
• 1389325-35-2 N-(1-(2-(4-chlorophenyl)-1-cyanobutan-2-yl)-1H-indol-4-yl)methanesulfonamide 
• 1389326-61-7 (E)-tert-butyl 1-(3-(4-chlorophenyl)-1-cyanopent-1-en-3-yl)-1H-indol-4-ylcarbamate 
• 1389326-62-8 (E)-4-(4-amino-1H-indol-1-yl)-4-(4-chlorophenyl)hex-2-enenitrile 
• 1389325-42-1 (E)-N-(1-(3-(4-chlorophenyl)-1-cyanopent-1-en-3-yl)-1H-indol-4-yl)methanesulfonamide 

Relevant academic research and scientific papers

Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists

Reported herein are a series of reverse indoles that represent novel non-steroidal mineralocorticoid receptor (MR) antagonists. The key structure-activity relationships (SAR) are presented below. This reverse indole series is exemplified by a compound tha

MINERALOCORTICOID RECEPTOR ANTAGONISTS

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophyl